The filing is a routine advance notice of a planned sale by a former affiliate, not a current executive or board member. The sale is small relative to market cap and appears to be a standard exercise-and-sell of options. No material impact is expected.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $174.41entry
- T+1 · 5d ago −2.87%α −2.52% · $169.40
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Sanjay Keswani, a former affiliate of Neurocrine Biosciences, filed a Form 144 notice of intent to sell 53,614 shares of common stock, with an approximate market value of $8.97 million based on the filing date. The shares were acquired through exercise of options under a registered plan, and the sale is planned for execution on the same day as the filing.
Key Facts
- Sanjay Keswani, a former affiliate, filed Form 144 to sell 53,614 shares of Neurocrine Biosciences common stock.
- The approximate market value of the proposed sale is $8,973,487.77.
- The shares were acquired through exercise of options under a registered plan on November 10, 2026.
- The sale is planned for execution on November 10, 2026, on the Nasdaq exchange.
- The filing represents about 0.05% of the company's $16.7B market cap.
Financial Impact
Proposed sale of 53,614 shares valued at approximately $8.97 million, representing about 0.05% of market cap.
Risk Factors
- The sale may signal the insider's desire to monetize options, but as a former affiliate, the signal is weaker than a current executive sale.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010964 |
| Document: 0001950047-26-010964-index.html | 0001950047-26-010964 |
| Document: 0001950047-26-010964.txt | 0001950047-26-010964 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Viewing Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers